Income statement
USD
Annual
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 9K | 6K | 21K |
| Gross Profit | 0 | 0 | 7K | 6K | 21K |
| Operating Income | -736K | -368K | -118K | -36K | 3K |
| EBITDA | -45K | -364K | -113K | -35K | 4K |
| Net Income | -781K | -270K | -118K | -36K | 2K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Regnum Corp. (RGMP) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -193.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -193.1%, free cash flow -5992.3% with operating margin 0.0% and ROIC -186.4%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RGMP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RGMP
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RGMP Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RGMP and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$21.4K
+239.7% YoY
FY Net Income
$2.0K
+105.5% YoY
Free Cash Flow
$3.2K
+108.1% YoY
Revenue Growth
+0.0%
EPS Growth
-193.1%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 9K | 6K | 21K |
| Gross Profit | 0 | 0 | 7K | 6K | 21K |
| Operating Income | -736K | -368K | -118K | -36K | 3K |
| EBITDA | -45K | -364K | -113K | -35K | 4K |
| Net Income | -781K | -270K | -118K | -36K | 2K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | 783K | 1M | 0 | 7K | 47K |
| Total Assets | 865K | 1M | 5K | 8K | 48K |
| Total Liabilities | 2M | 2M | 55K | 800 | 4K |
| Shareholder Equity | -1M | -380K | -50K | 8K | 44K |
| Total Debt | 2M | 2M | 0 | 0 | 0 |
| Net Debt | 773K | 22K | 0 | -7K | -47K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
4K
+110.4% YoY
Capital Expenditures
800
+20.0% YoY
Free Cash Flow
3K
+108.1% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
101.4%
Debt / Equity
-1.34x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.